CAMBRIDGE, Mass., April 30, 2013 /PRNewswire/ -- Moderna Therapeutics, the pioneering company developing messenger RNA therapeutics™—a revolutionary new treatment modality to enable the in vivo production of therapeutic proteins—announced today that Henri A. Termeer , Genzyme's retired chairman, president, and CEO, has joined Moderna's board of directors.
Over nearly 30 years at Genzyme, Termeer built one of the world's most innovative and commercially successful biotechnology companies. Under his leadership, Genzyme pioneered new models for sustainably bringing first-ever therapies to patients who were previously underserved. Termeer joins Moderna's board as the company embarks on the next phase of its growth strategy, strengthened by a strategic option agreement with AstraZeneca to develop new medicines for cardiometabolic diseases and by the continued progress of its preclinical programs in rare diseases and oncology.
"Messenger RNA therapeutics™ hold the same revolutionary potential as recombinant proteins did when they were first introduced nearly 30 years ago," said Noubar Afeyan , Chairman of Moderna's board and CEO of Flagship Ventures, the company's lead investor. "Henri's perspective will be invaluable as we work to deliver this new category of medicines for the treatment of serious diseases."
"It is an exciting time to be joining the board of Moderna, which I believe has the potential to transform the way in which protein therapeutics are developed, and to address diseases that are not currently reachable by recombinant technologies," Termeer said. "Moderna shares the same vision, ambition, and potential as many of the early biotechnology leaders. I look forward to helping the company deliver on its vast potential to improve the lives of patients across a wide array of disease areas."
"Henri has unparallel
|SOURCE Moderna Therapeutics|
Copyright©2012 PR Newswire.
All rights reserved